Loading...
•
Dec 31, 2025
GeneDx Holdings Corp Q4 2025 Earnings Report
GeneDx reported strong revenue growth in the fourth quarter of 2025, with expanding margins and positive adjusted net income, while GAAP results reflected a net loss.
Key Takeaways
GeneDx delivered Q4 2025 revenue of 120989000, up from 95640000 year over year, with adjusted gross margin expanding to 71.1% and adjusted net income of 4400000, while reporting a GAAP net loss of 17666000.
Total revenue increased to 120989000 from 95640000 year over year.
Exome and genome revenue grew to 104000000, up from 78800000 last year.
Adjusted gross margin expanded to 71.1% from 70.2%.
Adjusted net income was 4400000, while GAAP net loss was 17666000.
Revenue by Segment
Forward Guidance
For full year 2026, GeneDx expects revenue of 540000000 to 555000000, 33% to 35% growth in exome and genome revenue and volume, adjusted gross margin of at least 70%, and positive adjusted net income.
Positive Outlook
- Full year 2026 revenue guidance of 540000000 to 555000000.
- Expected 33% to 35% growth in exome and genome revenue.
- Expected 33% to 35% growth in exome and genome volume.
- Adjusted gross margin expected to be at least 70%.
- Adjusted net income expected to be positive.
Challenges Ahead
- GAAP net loss reported in Q4 2025.
- Operating loss in the quarter.
- High general and administrative expenses.
- Exposure to changes in fair value of financial liabilities.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...